New Publication Validates SeptiCyte® RAPID as a Triaging Tool for COVID-19 Patients

SeptiCyte RAPID accurately assessed COVID-19 severity Elevated SeptiScore upon hospital intake was predictive of ICU admission SeptiCyte RAPID performed better than single-biomarker assays that are routinely used to assess COVID-19 severity SEATTLE and BRISBANE, Australia, Feb. 2, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients,…

Read More

CEO Rolland Carlson: When Advancing a Medical Device, Be A Partner First & Seller Second to Hospital Systems

Immunexpress CEO Rolland Carlson was recently featured on HITConsultant, which provides healthcare technology news, analysis and insights for healthcare executives, physicians and providers. “US hospital systems validate the safety, clinical utility, and robustness of newly FDA-approved devices, 510(k) cleared, before adopting them into clinical practice. This work occurs alongside evaluating how to integrate the medical…

Read More

A Paradigm Shift in Sepsis Diagnostics

Technology Networks

By Anna MacDonald of Technology Networks Immunexpress is advancing next-generation clinical sepsis diagnosis tests for use in emergency room and intensive care unit settings. The company’s lead test SeptiCyte® RAPID is clinically validated and has received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. It is the first gene expression host response…

Read More

Tips For Obtaining Your 510(k) FDA Clearance

Med Device Online

By Rolland Carlson, Ph.D., CEO, Immunexpress Our SeptiCyte RAPID clinical test received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. Sepsis is a life-threatening medical condition. Every minute counts for these patients in the ER and ICU. Clinicians in these settings need processes to distinguish sepsis patients from infection-negative systemic inflammation and…

Read More

Immunexpress Announces the Launch of New SeptiCyte RAPID® CE-IVD EDTA Blood Compatible Cartridges

Immunexpress - the signature diagnostics for sepsis

SEATTLE, Aug. 23, 2022 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the launch of new SeptiCyte RAPID® EDTA blood compatible cartridges for the European market. The updated SeptiCyte® RAPID CE-IVD cartridge adds undiluted EDTA blood as a validated sample type, representing a significant development milestone for…

Read More

Immunexpress To Present at Biotech Showcase 2020 in San Francisco

Immunexpress.com

Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that its Chief Executive Officer, Rolland Carlson, Ph.D., will present at Biotech Showcase 2020, to be held January 13-15 at the Hilton San Francisco Union Square. Dr. Carlson will present an overview of the Company’s SeptiCyte™ technology and the…

Read More

Immunexpress Announces Grant of U.S. Patent Covering the Differentiation of Gram-Positive and Gram-Negative Sepsis-Causing Bacteria

Immunexpress.com

The patent includes classification techniques using single nucleotide polymorphisms (SNPs) in the ribosomal DNA of sepsis organisms Identification and classification of sepsis organisms leads to improved antibiotic decision-making SEATTLE, Nov. 21, 2019 – Immunexpress, Inc. today announced the U.S. Patent and Trademark Office (USPTO) has granted Patent No. U.S. 10,364,474 B2, which covers single nucleotide…

Read More